研究目的
To study the feasibility of a modified human serum albumin (HSA)-based radiotracer for identifying inflamed atherosclerotic lesions by in vivo molecular imaging.
研究成果
The modified HSA-based radiotracer showed in vivo targeting of inflamed atherosclerotic lesions in mouse aorta, suggesting 89Zr-Mal-HSA as a promising diagnostic tool for identifying vascular inflammation. Further studies are required to confirm its utility for detecting rupture-prone plaques.
研究不足
Further methodological studies are needed to verify the applicability of 89Zr-Mal-HSA for detecting rupture-prone plaques.
1:Experimental Design and Method Selection:
The study utilized a maleylated HSA (Mal-HSA) probe recognized by scavenger receptors on macrophages for in vivo imaging of atherosclerosis. The probe was coupled with Zirconium-89 (89Zr) for positron emission.
2:Sample Selection and Data Sources:
A mouse model of atherosclerosis (Apoe?/?, n=22) and wild-type (WT) mice (C57BL/6, n=21) were used.
3:List of Experimental Equipment and Materials:
PET-MRI for in vivo imaging, gamma counter for ex vivo biodistribution measurements, and phosphor imaging (PI) autoradiography (ARG) for plaque uptake evaluation.
4:Experimental Procedures and Operational Workflow:
Radiotracer accumulation was analyzed in vivo by PET-MRI, biodistribution was measured ex vivo by gamma counter, and plaque uptake was evaluated by PI-ARG.
5:Data Analysis Methods:
The maximum standardised uptake value (SUVmax) was calculated for comparison between groups.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容